Evofem Biosciences, Inc. · OTC:EVFM
Evofem Biosciences — Investor Presentation (February 2022)
18 slides from Evofem Biosciences's investor presentation, Feb 15, 2022
Slide 1: Revolutionizing Women's Sexual and Reproductive Health
Revolutionizing Women’s Sexual and Reproductive Health February 2022 NASDAQ: EVFM evofem.com © 2022 Evofem Biosciences, Inc. | For investor discussions only.
Slide 2: Forward-Looking Statements
© 2022 Evofem Biosciences, Inc. | For investor discussions only. Page | 2 Forward-Looking Statements This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. In some cases, you can identify for
Slide 3: Multi-billion addressable U.S. market opportunity
© 2022 Evofem Biosciences, Inc. | For investor discussions only. Page | 3 Multi-billion $$ addressable U.S. market opportunity for current and late-stage investigational indications Shattering the hormone glass ceiling with hormone-free, on-demand prescription contraceptive vaginal gel Top-line data
Slide 4: An Innovative Prescription Contraceptive
© 2022 Evofem Biosciences, Inc. | For investor discussions only. Page | 4 An Innovative Prescription Contraceptive • First-in-class vaginal pH modulator • FDA-approved for the prevention of pregnancy • Hormone-free • Applied 0-60 minutes before each act of sex • Box of 12 pre-filled applicators
Slide 5: Vaginal pH Modulator MOA
© 2022 Evofem Biosciences, Inc. | For investor discussions only. Page | 5 Vaginal pH Modulator MOA When semen (pH 7.1 - 8) enters the vagina, it raises the environmental pH level • Allows sperm to be mobile and swim up the reproductive canal Phexxi works to keep vaginal pH in the baseline range Vagi
Slide 6: $1.4B – $2.3B U.S. Opportunity
© 2022 Evofem Biosciences, Inc. | For investor discussions only. Page | 6 $1.4B – $2.3B U.S. Opportunity 1. Daniels K, Abma JC. Current contraceptive status among women aged 15-49: United States, 2015-2017. NCHS Data Brief. 2018; 327: 1-14. 2. Example market penetration in segment 3. Gross value of
Slide 7: User Demographics: We are Reaching Our Target Audience
© 2022 Evofem Biosciences, Inc. | For investor discussions only. Page | 7 User Demographics: We are Reaching Our Target Audience • 49% were not on a method of contraception in the past year • 29% switching from oral contraceptives • 7% switching from hormonal rings and patches Age demographic: early
Slide 8: Celebrity Campaign: Annie Murphy × Phexxi
© 2022 Evofem Biosciences, Inc. | For investor discussions only. Page | 8 Testimonial TELL HORMONES TO TAKE A HIKE. LEARN MORE AT PHEXXI.COM/ANNIE-MURPHY Celebrity Campaign: Annie Murphy × Phexxi
Slide 9: Strong Quarter over Quarter Growth: Prescriptions and Dispensed Units
© 2022 Evofem Biosciences, Inc. | For investor discussions only. Page | 9 81% INCREASE IN DISPENSED UNITS AND 69% TRx INCREASE IN Q4 VS. Q3 Strong Quarter over Quarter Growth: Prescriptions and Dispensed Units 0 5,000 10,000 15,000 20,000 25,000 30,000 35,000 40,000 45,000 Q4 2020 Q1 2021 Q2 2021 Q3
Slide 10: Strong Fourth Quarter 2021 Results (preliminary)
© 2022 Evofem Biosciences, Inc. | For investor discussions only. Page | 10 Strong Fourth Quarter 2021 Results (preliminary) Net product sales ~$3.5M – more than double Q3 Net cash burn ~$17M – down ~$15M from $32.0M in Q3 Q4’21 Increase vs. Q3’21 Phexxi units dispensed 39,121 81% Phexxi total prescr
Slide 11: 2022 Key Initiatives
© 2022 Evofem Biosciences, Inc. | For investor discussions only. Page | 11 2022 Key Initiatives Increase access to Phexxi in U.S. Continue to improve GTN Enter licensing agreements to get Phexxi into international markets Drive our chlamydia & gonorrhea prevention program forward Reduce cash burn an
Slide 12: I. Increase Access to Phexxi in U.S.
© 2022 Evofem Biosciences, Inc. | For investor discussions only. Page | 12 I. Increase Access to Phexxi in U.S. Affordable Care Act (ACA) mandates coverage without any out-of- pocket costs for 18 specific methods of contraception listed on FDA birth control guide Jan. 2022: HSRA and Department of La
Slide 13: Value Creating Opportunities
© 2022 Evofem Biosciences, Inc. | For investor discussions only. Page | 13 Value Creating Opportunities Secure partnership(s) for commercialization of Phexxi in foreign markets • Discussions ongoing with potential global and regional partners for key international markets • Anticipated structure - U
Slide 14: Pipeline
© 2022 Evofem Biosciences, Inc. | For investor discussions only. Page | 14 Pre-Clinical Phase I Phase 2 Phase 3 Regulatory Filing Phexxi: Urogenital Chlamydia in Women (prevention) Expected Q1 20231 Phexxi: Urogenital Gonorrhea in Women (prevention) Expected Q1 20231 EVO-200: Recurrent Bacterial Vag
Slide 15: Lead Opportunity: Prevention of Chlamydia & Gonorrhea
© 2022 Evofem Biosciences, Inc. | For investor discussions only. Page | 15 Lead Opportunity: Prevention of Chlamydia & Gonorrhea 1. US Centers for Disease Control and Prevention (2019): CDC detailed fact sheet on gonorrhea and CDC detailed fact sheet on chlamydia 2. Daniels K, Abma JC. Current contr
Slide 16: Timeline - Prevention of Chlamydia & Gonorrhea
© 2022 Evofem Biosciences, Inc. | For investor discussions only. Page | 16 Timeline - Prevention of Chlamydia & Gonorrhea Fast Track Review 2022 2023 2024 Potential U.S. Approval & Commercial Launch3 FDA Submission2Top-Line Results1 Complete Enrollment1 1. Assumes timely enrollment 2. Assumes favora
Slide 17: 2022 Catalysts and Milestones
© 2022 Evofem Biosciences, Inc. | For investor discussions only. Page | 17 2022 Catalysts and Milestones ● Q4 and YE 2021 results March ● Complete enrollment in Phase 3 STI trial March ● Ex-U.S. licensing agreement(s) 1H 2022 ● Top-line results from Phase 3 STI trial 2H 2022 ● Stability data: MPT va
Slide 18: Thank You
1.858.550.1900 ir@evofem.com 12400 High Bluff Drive, Suite 600 San Diego, California 92130 NASDAQ: EVFM evofem.com Thank You
Evofem Biosciences — Investor Presentation (February 2022) on 6ix